Precision BioSciences (NASDAQ:DTIL) CEO Sells $22,124.41 in Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 3,409 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $6.49, for a total transaction of $22,124.41. Following the sale, the chief executive officer directly owned 115,575 shares in the company, valued at approximately $750,081.75. The trade was a 2.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Precision BioSciences Stock Down 2.7%

Precision BioSciences stock opened at $6.44 on Friday. The firm has a market capitalization of $85.39 million, a P/E ratio of -0.77 and a beta of 1.79. The company has a current ratio of 3.45, a quick ratio of 5.18 and a debt-to-equity ratio of 1.35. Precision BioSciences, Inc. has a twelve month low of $3.61 and a twelve month high of $8.82. The stock’s fifty day simple moving average is $5.85 and its 200-day simple moving average is $5.20.

Precision BioSciences (NASDAQ:DTIL) last issued its quarterly earnings results on Monday, November 3rd. The company reported ($1.84) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($1.53). The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $5.40 million. Precision BioSciences had a negative return on equity of 233.77% and a negative net margin of 11,977.36%.During the same quarter last year, the company earned ($2.25) EPS. As a group, equities analysts expect that Precision BioSciences, Inc. will post -1.23 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Precision BioSciences in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $47.00.

Institutional Trading of Precision BioSciences

A number of large investors have recently bought and sold shares of DTIL. Miller Financial Services LLC acquired a new position in Precision BioSciences in the first quarter valued at $48,000. Vanguard Personalized Indexing Management LLC acquired a new position in Precision BioSciences in the 3rd quarter valued at $72,000. Bridgeway Capital Management LLC acquired a new stake in shares of Precision BioSciences in the 2nd quarter worth $260,000. Tejara Capital Ltd boosted its holdings in shares of Precision BioSciences by 185.2% in the first quarter. Tejara Capital Ltd now owns 60,427 shares of the company’s stock valued at $288,000 after acquiring an additional 39,242 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Precision BioSciences by 5.5% during the second quarter. Geode Capital Management LLC now owns 77,712 shares of the company’s stock worth $326,000 after acquiring an additional 4,025 shares during the period. Institutional investors and hedge funds own 37.99% of the company’s stock.

About Precision BioSciences

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.